Aktuelle Urol 2002; 33(6): 435-441
DOI: 10.1055/s-2002-35020
Übersichtsarbeit
© Georg Thieme Verlag Stuttgart · New York

Genitale Infektionen mit humanen Papillomaviren (HPV)

Genital Infections Caused by Human Papillomaviruses (HPV)H.  Büttner1 , D.  Jocham1 , A.  Böhle1
  • 1Klinik und Poliklinik für Urologie, Universitätsklinikum Lübeck (Direktor: Prof. Dr. med. D. Jocham)
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. Oktober 2002 (online)

Zusammenfassung

Condylomata acuminata sind die häufigste Ausdrucksform genitoanaler Infektionen mit humanen Papillomaviren (HPV). Zugleich stellt diese Infektion die häufigste sexuell übertragbare Erkrankung dar. Unter den derzeit mehr als 100 bekannten Subtypen finden sich so genannte Low-risk-Typen (vornehmlich HPV 6 und 11), die externe genitoanale Warzen hervorrufen und onkogene High-risk-Typen (insbesondere HPV 13, 16, 18, 31, 33 und 35), die in bis zu 100 % aller Fälle mit prämalignen und invasiven Läsionen des Genitoanalbereiches assoziiert sind. Die aktuellen diagnostischen Verfahren wie auch die derzeitig verfügbaren Therapiemodalitäten werden dargestellt. Die meisten Verfahren führen zu einer lokalen Gewebezerstörung, entweder durch zytotoxische Wirkung oder physikalisch-ablativ. Interferone besitzen antivirale, antiproliferative und immunmodulatorische Eigenschaften, doch führen diese bisher nicht zu effektiven Heilungsraten. Allen gängigen Therapieverfahren eigen sind zudem hohe Rezidivraten gemeinsam. Einen Ausblick stellen innovative immuntherapeutische Ansätze sowie die Darstellung der Vakzinierungsstrategien dieser weltweit an Bedeutung zunehmenden Infektionen dar.

Abstract

Condylomata acuminata are the most prevalent expression of genito-anal infections caused by human papillomavirus (HPV), the most common sexually transmitted disease. To date more than 100 subtypes are classified among which the high-risk-types (HPV 6 and 11) are mostly associated with genital warts. Oncogenic high-risk HPV (13, 16, 18, 31, 33 and 35) are found in premalign and malign genito-anal lesions. Although many treatments are available for genital warts, none are uniformly successful in the treatment of this disease. Most current treatment options work by destroying affected tissue, either by a cytotoxic or a physically ablative mode of action. Interferons have antiviral, antiproliferative, and immunomodulatory activities, but these have not translated into a high level of cure rates against warts. With all current treatments, recurrent warts are common. New treatment modalities focus on activating the host's immune system and perhaps the most effective means for managing HPV disease would be a vaccine that prevents the occurrence of genital warts.

Literatur

  • 1 Bosch F X, Manos M M, Munoz N, Sherman M, Jansen A M, Peto J, Schiffman M H, Moreno V, Kurman R, Shah K V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.  J Natl Cancer Inst. 1995;  87 796-802
  • 2 Walboomers J M, Jacobs M V, Manos M M, Bosch F X, Kummer J A, Shah K V, Snijders P F, Peto J, Meijer C J, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;  189 12-19
  • 3 Frisch M, Fenger C, van den Brule A J, Sorensen P, Meijer C J, Walboomers J M, Adami H O, Melbye M, Glimelius B. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus.  Cancer Res. 1999;  59 753-757
  • 4 Andersson S, Rylander E, Larsson B, Strand A, Silfversvärd D, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis.  Eur J Cancer. 2001;  37 246-250
  • 5 Cupp M R, Malek R S, Goellner J R, Smith T F, Espy M J. The detection of human papillomavirus deoxyribonucleide acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis.  J Urol. 1995;  154 1024-1029
  • 6 Walboomers J M. Human papillomavirus detection and cervical cancer screening.  Pathologia. 1999;  32 270
  • 7 Koutsky L A. Epidemiology of genital human papillomavirus infection.  Am J Med. 1997;  102 3-8
  • 8 Jacobs M V, Walboomers J M, Snijders P J, Voorhorst F J, Verheijen R H, Fransen-Daalmeijer N, Meijer C J. Distribution of 37 mucosatropic HPV types in women with cytologically normal cervical smears: the age-related pattern for high-risk and low-risk-types.  Int J Cancer. 2000;  87 221-227
  • 9 Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E, Rylander E, Wadell G. Lifetime number of partners as the only independent risk factor for human papillomavirus-infection: a population based study.  Sex Transm Dis. 1995;  22 119-126
  • 10 Ishi K, Suzuki F, Saito A, Kubota T. Prevalence of human papillomavirus, Chlamydia trachomatis, and Neisseria gonorrhoeae in commercial sex workers in Japan.  Infect Dis Obstet Gynecol. 2000;  8 235-239
  • 11 Silins I, Kallins I, Dillner J. Correlates of the spread of human papillomavirus infection.  Cancer Epidemiol Biomarkers Prev. 2000;  9 953-959
  • 12 Ylitalo N, Josefsson A, Melbye M, Sorensen P, Frisch M, Andersen P K, Sparen P, Gustafsson M, Magnusson P, Ponten J, Gyllensten U, Adami H O. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ.  Cancer Res. 2000;  60 6027-6032
  • 13 Eluf-Neto J, Nascimento C M. Cervical cancer in Latin America.  Semin Oncol. 2001;  28 188-197
  • 14 Mork J, Lie A K, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller Y T, Youngman L, Lehtinen M, Dillner J, Clark S, Wang Z. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.  N Engl J Med. 2001;  344 1125-1131
  • 15 Gillison M L, Shah K V. Human papillomvirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers.  Curr Opin Oncol. 2001;  13 183-188
  • 16 Griffiths T RL, Mellon J K. Human papillomavirus and urological tumours: I. Basic science and role in penile cancer.  BJU Int. 1999;  84 (Suppl) 579-586
  • 17 Griffiths T RL, Mellon J K. Human papillomvirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer.  BJU International. 2000;  85 211-217
  • 18 Westend P J, Stoop J A, Hendriks J GM. Human papillomaviruses 6/11, 168 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder.  BJU International. 2001;  88 198-201
  • 19 Coleman N, Birley H D, Renton A M, Hanna N F, Ryait B K, Byrne M, Tasylor-Robinson D, Stanley M A. Immunological events in regressing genital warts.  Am J Clin Pathol. 1994;  102 768-774
  • 20 Malejczyk J, Majewski S, Jablonska S. The regulatory influence of immunological host responses. In: Gross G, von Krogh G (Hrsg.). Human Papillomavirus Infections in Dermatovenerology. Coba Raton: CRC Press 1995: 203-226
  • 21 Rudlinger R, Smith I, Bunney M, Hunter J. Human papillomavirus infections in a group of renal transplant patients.  Br J Derm. 1986;  115 681-692
  • 22 West A F, Leung H Y, Powell P H. Pan-urethral warts as a cause of acute retention of urine.  BJU International. 1999;  84 1100-1101
  • 23 Rosemberg S K. Subclinical papilloma viral infection of male genitalia.  Urology. 1985;  26 554-557
  • 24 Fehr M K, Champman C F, Krasieva T, Tromberg B J, McCullogh J L, Berns M W, Tadir Y. Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid.  Am J Obstet Gynecol. 1996;  174 951-957
  • 25 Ross E V, Romero R, Kollias N, Crum C, Anderson R R. Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolyevulinic acid: implications for photodynamic treatment.  Br J Dermatol. 1997;  137 736-742
  • 26 Schneede P, Leunig A, Hillemanns P, Wagner S, Hofstetter A G. Photodynamic investigation of mucosa-associated human papillomavirus efflorescence.  BJU International. 2001;  88 117-119
  • 27 Gross G, Korting H C, Schöfer H, Szeimies R M, Eibisch M A, Ikenberg H, Petry K U, Schneede-Pfister H. Leitlinie der Deutschen STD-Gesellschaft (DSTDG) Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder des Genitale und der Harnröhre. URL: www-duk.med.uni-rostock.de/duk_hpv.htm#Kopf1. 2000
  • 28 Ledger W J, Jeremias J, Witkin S S. Testing for high-risk human papillomavirus types will become a standard for clinical care.  Am J Obstet Gynecol. 2000;  182 860-865
  • 29 Brennan M M, Lambkin H A, Sheehan C D, Ryan D D, O'Connor T C, Kealy W F. Detection of high-risk subtypes of human papillomavirus in cervical swabs: routine use of the Digene Hybrid Capture assay and polymerase chain reaction analysis.  Br J Biomed Sci. 2001;  58 24-29
  • 30 Fralick R A, Malek R S, Goeller J R, Hyland K M. Urethroscopy and urethral cytology in men with external genital condyloma.  Urology. 1994;  43 361-364
  • 31 Zvulunov A, Medvedovsky E, Biton A, Horowitz S, Vardy D. Association of Ureaplasma uralyticum colonization in male urethra and Condyloma acuminatum.  Isr Med Assoc J. 2000;  2 580-582
  • 32 Lorenzato F, Ho L, Terry G, Singer A, Santos L C, De Lucena Batista R, Lubambo T. The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil).  Int J Gynecol Cancer. 2000;  10 143-150
  • 33 Nathan P M, Thompson V C, Sharmacharja G, Hawkswell J, Fogarty B. A study of the prevalence of male intrameatal warts using meatoscopy in a genitourinary medicine department.  Int J STD AIDS. 1995;  6 184-187
  • 34 Kaplinsky R S, Pranikoff K, Chasan S, DeBerry J L. Indications for urethroscopy in male patients with penile condylomata.  J Urol. 1995;  153 1120-1121
  • 35 von Krogh G, Lacey C J, Gross G, Barrasso R, Schneider A. European Course on HPV-Associated Pathology: Guidelines for the diagnosis and management of anogenital warts.  Sex Transm Inf. 2000;  76 162-168
  • 36 Beutner K R, Spruance S L, Hougham A J, Fox T L, Owens M L, Douglas Jr J M. Treatment of genital warts with an immune-response modifier (imiquimod).  J Am Acad Dermatol. 1998;  38 230-239
  • 37 Perry C M, Lamb H M. Topical imiquimod: a review of its use in genital warts.  Drugs. 1999;  58 375-390
  • 38 Langley P C, Tyring S K, Smith M H. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts.  Am J Manag Care. 1999;  5 69-77
  • 39 Gross G, Rogozinski T, Schofer H, Jablonska S, Roussaki A, Wohr C, Broska J. Recombinant interferon β gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients.  Dermatology. 1998;  196 330-334
  • 40 Boehle A, Doehn C, Kausch I, Jocham D. Treatment of recurrent penile condylomata acuminata with external application and intraurethral instillation of bacillus Calmette-Guerin.  J Urol. 1998;  160 394-396
  • 41 Boehle A, Büttner H, Jocham D. Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin.  J Urol. 2001;  165 834-836
  • 42 Offringa R, van der Burg S H, Ossendorp F, Toes R EM, Melief C JM. Design and evaluation of antigen-specific vaccination strategies against cancer.  Curr Opin Immunol. 2000;  12 576-582
  • 43 Borysiewiecz L K, Fiander A, Nimako M, Man S, Wilkinson G W, Westmoreland D, Evans A S, Adams M, Stacey S N, Boursnell M E, Rutherford E, Hickling J K, Inglis S C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.  Lancet. 1996;  347 1523-1527
  • 44 Steller M A, Gurski K J, Murakami M, Daniel R W, Shah K V, Celis E, Sette A, Trimble E L, Park R C, Marincola F M. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidaed epitope of human papillomavirus type 16 E7.  Clinc Cancer Res. 1998;  4 2103-2109
  • 45 De Gruijl T D, Bontkes H J, Walboomers J M, Coursaget P, Stukart M J, Dupuy C, Kueter E, Verheijen R H, Helmerhorst T J, Duggan-Keen M F, Stern P L, Meijer C J, Scheper R J. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.  J Gen Virol. 1999;  80 399-408
  • 46 Bontkes H J, de Gruijl T D, Walboomers J M, Schiller J T, Dillner J, Helmerhorst T J, Verheijen R H, Scheper R J, Meijer C J. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.  J Gen Virol. 1999;  80 409-417
  • 47 Van Driel W J, Ressing M E, Kenter G G, Brandt R M, Krul E J, van Rossum A B, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam P A, Fleuren G J, Kast W M, Melief C J, Trimbos J B. Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I - II trial.  Eur J Cancer. 1999;  35 946-952
  • 48 Ressing M E, van Driel W J, Brandt R M, Kenter G G, de Jong J H, Bauknecht T, Fleuren G J, Hoogerhout P, Offinga R, Sette A, Cilis E, Grey H, Trimbos B J, Kast W M, Melief C J. Detection of T-helper responses, but not of human papillomavirus-specific cytotoxic T-lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.  J Immunother. 2000;  23 255-266
  • 49 Thompson H S, Davies M L, Holding F P, Fallon R E, Mann A E, O'Neill T, Roberts J S. Phase I safety and antigenicity of TA-GW: a rebombinant HPV 6 L2E7 vaccine for the treatment of genital warts.  Vaccine. 1999;  17 40-49
  • 50 Lacey C J, Thompson H S, Monteiro E F, O'Neill T, Davies M L, Holding F P, Fallon R E, Roberts J S. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts.  J Infect Dis. 1999;  179 612-618
  • 51 Christensen N D, Han R, Cladel C M, Pickel M D. Combination treatment with intralesional cidofvir and vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences.  Antimicrob Agents Chemother. 2001;  45 1201-1209
  • 52 Beutner K R. Therapeutic Approaches to Genital Warts.  Am J Med. 1997;  102 28-37

OA Dr. med. H. Büttner

Klinik und Poliklinik für Urologie · Universitätsklinikum Lübeck

Ratzeburger Allee 160

23538 Lübeck

Telefon: 0451/500-6113/6114

Fax: 0451/500-4666

eMail: hartwig.buettner@medinf.mu-luebeck.de

    >